Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
none reported
|
| gptkbp:annualVisitors |
not publicly disclosed
|
| gptkbp:awards |
received industry recognition
|
| gptkbp:businessModel |
focused on drug development.
|
| gptkbp:CEO |
gptkb:Michael_Kauffman
|
| gptkbp:clinicalTrials |
oncology
various countries ongoing efforts Phase 1, Phase 2, Phase 3 various phases published in journals innovative methodologies multiple ongoing focused on innovative therapies clinical stage |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
active in local initiatives
|
| gptkbp:communityPartnerships |
with healthcare organizations
|
| gptkbp:drugInterdiction |
ongoing applications
|
| gptkbp:employees |
over 100
|
| gptkbp:financialPerformance |
varies with market conditions
|
| gptkbp:financials |
quarterly and annual reports
|
| gptkbp:focus |
cancer treatment
|
| gptkbp:focusesOn |
nuclear transport inhibitors
|
| gptkbp:founded |
2010
|
| gptkbp:founder |
gptkb:Michael_Kauffman
|
| gptkbp:hasPrograms |
comprised of industry experts
|
| gptkbp:headquarters |
gptkb:Newton,_Massachusetts
|
| gptkbp:healthcare |
collaborates with advocacy groups
|
| gptkbp:historicalResearch |
with leading scientists
focused on cancer biology |
| https://www.w3.org/2000/01/rdf-schema#label |
Karyopharm Therapeutics
|
| gptkbp:investmentFocus |
regular updates
various venture capital firms active engagement significant funding rounds |
| gptkbp:leadership |
experienced executives
|
| gptkbp:leads |
Selinexor
|
| gptkbp:market |
approximately $200 million
growing in oncology sector |
| gptkbp:notableEvent |
Selinexor
|
| gptkbp:partnerships |
research institutions
various pharmaceutical companies |
| gptkbp:patentCitation |
multiple granted patents
|
| gptkbp:patentType |
Selinexor in 2019
|
| gptkbp:publications |
numerous scientific papers
|
| gptkbp:regulatoryCompliance |
publicly traded
adheres_to_FDA_guidelines |
| gptkbp:research |
secured from various sources
|
| gptkbp:research_areas |
hematologic malignancies
multiple cancers |
| gptkbp:researchAndDevelopment |
ongoing
|
| gptkbp:researchFocus |
nuclear transport
|
| gptkbp:stockSymbol |
KPTI
|
| gptkbp:strategicGoals |
expand product pipeline
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple drug candidates
|
| gptkbp:website |
www.karyopharm.com
|